GlassScriptPhysician profile
Mark P Albright
NPI 1104824259
$4,626.57
in general payments reported to CMS, 2019-2025
34 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $293 · 2021: $226 · 2022: $519 · 2023: $955 · 2024: $972 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.67 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $940.19 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $480.02 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $358.39 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $275.49 | 2020-2023 | Krystexxa |
| Novo Nordisk INC | $224.24 | 2024-2025 | Rivfloza, Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $199.12 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $192.92 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $185.16 | 2019-2024 | Ultomiris |
| Travere Therapeutics, INC. | $180.76 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $160.50 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $157.38 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $155.68 | 2021-2025 | Benlysta |
| Daiichi Sankyo INC. | $128.31 | 2020-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.86 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $112.21 | 2019-2025 | Velphoro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $108.90 | 2020-2025 | Terlivaz, Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.45 | 2024-2025 | Jynarque |
| Ardelyx, INC. | $81.99 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $81.88 | 2022-2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $62.59 | 2022-2024 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $44.84 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $43.16 | 2021-2022 | |
| Lilly USA, LLC | $39.81 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $35.70 | 2019-2023 | Rayaldee |
| Genzyme Corporation | $26.30 | 2023 | |
| Nxstage Medical, INC. | $26.04 | 2024 | |
| Scpharmaceuticals INC. | $18.98 | 2025 | |
| Outset Medical INC | $18.60 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.71 | 2023 | Givlaari |
| Akebia Therapeutics INC | $15.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.46 | 2019 | |
| La Jolla Pharmaceutical Company | $14.85 | 2019 | |
| Ascendis Pharma Endocrinology INC | $14.85 | 2025 | Yorvipath |
| Amicus Therapeutics, INC. | $13.56 | 2024 | Galafold |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Albright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.